Access to Cancer Medicines in China: A Regional Snapshot

China rolled out a national price‑cut program for drugs in 2016 to make cancer treatments cheaper and easier to get. The plan has helped more people buy life‑saving medicines, but it is not working equally across the country. In a recent study researchers looked at how well patients in different regions can actually obtain drugs that were included in the price talks. They compared what is available, how much it costs, and who ends up buying the medicine in each area. The findings show that cities in the east coast, where hospitals are bigger and funding is higher, have far better access to discounted drugs than towns in the interior or on the western borders. Even within a province, some hospitals get more drugs than others because of how they are linked to national supply chains.The researchers used a statistical tool called decomposition analysis to separate the reasons behind these gaps. Part of the difference comes from how hospitals are paid: wealthier regions receive more money for drug purchases. Another part is due to the way drugs are distributed; some areas have better logistics and storage facilities that keep medicines safe and ready. These insights suggest that simply cutting prices is not enough to level the playing field. Policymakers need to strengthen funding for poorer regions and improve supply‑chain infrastructure so that patients everywhere can benefit from the negotiated prices. Overall, the study warns that without targeted support, the price‑cut program could widen existing health inequalities instead of closing them. It calls for a more balanced approach that looks beyond price and tackles regional disparities head‑on.